[go: up one dir, main page]

WO2010116866A1 - Agent permettant d'améliorer ou de prévenir le syndrome métabolique - Google Patents

Agent permettant d'améliorer ou de prévenir le syndrome métabolique Download PDF

Info

Publication number
WO2010116866A1
WO2010116866A1 PCT/JP2010/054446 JP2010054446W WO2010116866A1 WO 2010116866 A1 WO2010116866 A1 WO 2010116866A1 JP 2010054446 W JP2010054446 W JP 2010054446W WO 2010116866 A1 WO2010116866 A1 WO 2010116866A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucan
metabolic syndrome
molecular weight
preventing agent
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2010/054446
Other languages
English (en)
Japanese (ja)
Inventor
千賀子 清水
拓 平田
誠 木原
茂樹 荒木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapporo Breweries Ltd
Original Assignee
Sapporo Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Breweries Ltd filed Critical Sapporo Breweries Ltd
Publication of WO2010116866A1 publication Critical patent/WO2010116866A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Definitions

  • the present invention relates to an agent for improving or preventing metabolic syndrome.
  • metabolic syndrome a state in which lifestyle-related diseases such as hypertension, hyperlipidemia, and diabetes have occurred due to visceral fat accumulation
  • arteriosclerotic diseases myocardial infarction, cerebral infarction, etc.
  • an agent for improving or preventing metabolic syndrome for example, an agent containing a dietary fiber aggregate having a maximum content of water-soluble ⁇ -glucan as an active ingredient is known (see Patent Document 1).
  • an object of the present invention is to provide a novel metabolic syndrome improving or preventing agent that is highly safe for living bodies and can be ingested daily and continuously.
  • the present inventors have found that, when a ⁇ -glucan degradation product obtained by subjecting a barley pulverized product to a certain treatment is administered to a living body, symptoms of metabolic syndrome including visceral fat accumulation are strongly suppressed, The present invention has been completed.
  • the present invention provides an agent for improving or preventing metabolic syndrome, which contains a degradation product of ⁇ -1,3-1,4-glucan as an active ingredient, and the degradation product has a weight average molecular weight of 1000 Da or more and less than 50000 Da.
  • the “degradation product” of ⁇ -1,3-1,4-glucan refers to a compound produced by enzymatic or chemical hydrolysis of ⁇ -1,3-1,4-glucan. It shall be said.
  • the metabolic syndrome improving or preventing agent of the present invention makes it possible to suppress visceral fat accumulation and suppress fat cell hypertrophy. It also makes it possible to suppress the accumulation of triglycerides and cholesterol. And, through such an action, visceral fat type obesity or metabolic syndrome can be improved (treated, reduced) and prevented.
  • “inhibition of accumulation” of visceral fat refers to suppressing increase of visceral fat or reducing visceral fat.
  • “suppression of accumulation” of triglyceride or cholesterol refers to suppressing or reducing the increase of triglyceride or cholesterol in the body.
  • the metabolic syndrome improving or preventing agent of the present invention has a visceral fat accumulation inhibitory action and an adipocyte hypertrophy inhibitory action, it can also be used as a visceral fat accumulation inhibitor or an adipocyte hypertrophy inhibitor. Moreover, since it has a triglyceride accumulation inhibitory action and a cholesterol accumulation inhibitory action, it can also be used as a triglyceride accumulation inhibitor or a cholesterol accumulation inhibitor.
  • the metabolic syndrome improving or preventing agent of the present invention is highly safe to the living body and can be ingested daily and continuously, and as a component of pharmaceuticals, foods and drinks, food and drink additives, feeds, feed additives and the like Suitable for use.
  • ⁇ -1,3-1,4-glucan degradation products having a weight average molecular weight of 1000 Da or more and less than 50000 Da are more water-soluble than high molecular weight ⁇ -1,3-1,4-glucan, The viscosity is low.
  • the metabolic syndrome improving or preventing agent of the present invention is suitable for use as a component of pharmaceuticals, foods and drinks, food and drink additives, feeds, feed additives and the like.
  • the present invention also provides a composition containing a degradation product of ⁇ -1,3-1,4-glucan, wherein the degradation product has a weight average molecular weight of 1000 Da or more and less than 50000 Da.
  • a composition can be used for the preparation of the above-described metabolic syndrome improving or preventing agent.
  • the composition may be composed of a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da.
  • the composition is an ⁇ -amylase treatment step of decomposing the pulverized plant containing ⁇ -1,3-1,4-glucan with ⁇ -amylase; a ⁇ -glucan degradation step of degrading ⁇ -1,3-1,4-glucan in the reaction mixture obtained in the ⁇ -amylase treatment step with ⁇ -glucanase and / or cellulase; It can obtain by the manufacturing method containing. Such a manufacturing method is also included in the present invention.
  • the above production method is obtained in the ⁇ -amylase treatment step.
  • the fraction acquisition step of obtaining a ⁇ -1,3-1,4-glucan-containing fraction from the obtained reaction mixture was performed after the ⁇ -amylase treatment step, and the obtained ⁇ -1,3-1,4-glucan was obtained.
  • the contained fraction is preferably subjected to a ⁇ -glucan decomposition step.
  • the plant containing ⁇ -1,3-1,4-glucan has a high content of ⁇ -1,3-1,4-glucan.
  • Barley, oats, rye, wheat, wheat) are preferred.
  • a plant seed pulverized product is suitable.
  • a novel metabolic syndrome improving or preventing agent that is highly safe for living organisms and can be taken daily and continuously.
  • the pharmaceutical, food / beverage products, food / beverage product additive, feed, feed additive, etc. containing such a metabolic syndrome improvement or prevention agent are provided.
  • the novel composition which can be used for preparation of such a metabolic syndrome improvement or prevention agent, and its manufacturing method are provided.
  • 3 is a molecular weight distribution curve of a ⁇ -1,3-1,4-glucan degradation product obtained by refractive index (RI) analysis of decomposed ⁇ -glucan powder.
  • 2 is a graph showing plasma triglyceride values of mice administered with a ⁇ -1,3-1,4-glucan degradation product.
  • 2 is a graph showing plasma total cholesterol levels of mice administered with ⁇ -1,3-1,4-glucan degradation products.
  • 2 is a graph showing fat weight around the epididymis of mice administered with ⁇ -1,3-1,4-glucan degradation product.
  • 2 is a graph showing the weight of fat in the back abdominal wall of mice administered with ⁇ -1,3-1,4-glucan degradation product.
  • 2 is a graph showing the size of mesenteric adipocytes in mice administered with a ⁇ -1,3-1,4-glucan degradation product.
  • 2 is a graph showing the total amount of lipids in feces of mice administered with ⁇ -1,3-1,4-glucan degradation product.
  • 3 is a graph showing the total amount of cholesterol in feces of mice administered with ⁇ -1,3-1,4-glucan degradation product.
  • 2 is a graph showing the amount of bile acids in feces of mice administered with ⁇ -1,3-1,4-glucan degradation product.
  • the metabolic syndrome improving or preventing agent of the present invention contains a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da as an active ingredient.
  • metabolic syndrome refers to a state in which visceral fat is accumulated and any lifestyle-related diseases such as hypertension, hyperlipidemia, and diabetes develop.
  • any lifestyle-related diseases such as hypertension, hyperlipidemia, and diabetes develop.
  • the requirements of “waist circumference: male ⁇ 85 cm, female ⁇ 90 cm (both male and female are equivalent to visceral fat area ⁇ 100 cm 2 )” are satisfied, and the following (1) to (3
  • the metabolic syndrome can be diagnosed if at least two of the above requirements are met (see Journal of the Japan Society for Internal Medicine, 94 (4), 794-809, 2005).
  • Lipoprotein abnormality hypertriglyceridemia (triglyceride level ⁇ 150 mg / dL) and / or low HDL cholesterolemia (HDL cholesterol level ⁇ 40 mg / dL)
  • High blood pressure systolic blood pressure ⁇ 130 mmHg and / or diastolic blood pressure ⁇ 85 mmHg
  • Hyperglycemia Fasting blood glucose ⁇ 110 mg / dL
  • ⁇ -1,3-1,4-glucan may be derived from, for example, a plant or a microorganism (bacteria, fungus, etc.).
  • Natural products for obtaining ⁇ -1,3-1,4-glucan are, for example, gramineous plants (for example, barley, oats) in terms of a high content of ⁇ -1,3-1,4-glucan.
  • Wheat, rye, wheat and wheat are preferred, and barley and oats are particularly preferred.
  • seeds are suitable (any of whole grains, endosperm, cocoons, etc.).
  • the degradation product of ⁇ -1,3-1,4-glucan having a weight average molecular weight of 1000 Da or more and less than 50000 Da is, for example, a high molecular weight ⁇ -1,3-1,4-glucan obtained by treating barley seed ground with ⁇ -amylase. It can be obtained by obtaining a fraction containing it and further treating it with ⁇ -glucanase and / or cellulase.
  • the ⁇ -amylase treatment of the barley seed pulverized product is performed, for example, by mixing a mixture of barley seed pulverized product, ⁇ -amylase and water at 40 to 100 ° C. In this case, it can be carried out by stirring at 40 to 80 ° C. for 15 to 90 minutes.
  • a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da can be obtained.
  • the treatment with ⁇ -amylase and the treatment with ⁇ -glucanase and / or cellulase may be performed simultaneously.
  • such simultaneous treatment may be performed by pulverizing barley seeds, ⁇ -amylase, ⁇ -glucanase, and water. This can be done by stirring the mixture (cellulase may be used with or instead of ⁇ -glucanase).
  • the ⁇ -1,3-1,4-glucan degradation product may have a weight average molecular weight of 1000 Da or more and less than 50000 Da, and the weight average molecular weight is preferably, for example, 1500 Da or more and 30000 Da or less, and 2000 Da or more. 20000 Da or less is more preferable, 3000 Da or more and 10,000 Da or less is further preferable, and 3000 Da or more and 6000 Da or less is more preferable.
  • the weight average molecular weight of the ⁇ -1,3-1,4-glucan degradation product can be measured by a known method (for example, gel permeation chromatography (GPC), gel filtration chromatography (GFC)).
  • GPC gel permeation chromatography
  • GFC gel filtration chromatography
  • the calibration curve used for determination of a weight average molecular weight can be created, for example using the standard product of a pullulan.
  • the metabolic syndrome improving or preventing agent of the present invention may be in any form of solid (for example, powder), liquid (water-soluble or fat-soluble solution or suspension), paste, etc., and powders, granules, tablets , Capsules, solutions, suspensions, emulsions, ointments, plasters and the like. Further, the metabolic syndrome improving or preventing agent of the present invention may comprise a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da.
  • the above-mentioned various preparations include a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da, and pharmaceutically acceptable additives (excipients, binders, lubricants, disintegrations). Agents, emulsifiers, surfactants, bases, solubilizers, suspending agents, and the like).
  • examples of the excipient include lactose, sucrose, starch, dextrin and the like.
  • the binder include polyvinyl alcohol, gum arabic, tragacanth, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and the like.
  • examples of the lubricant include magnesium stearate, calcium stearate, talc and the like.
  • examples of the disintegrant include crystalline cellulose, agar, gelatin, calcium carbonate, sodium bicarbonate, dextrin and the like.
  • the emulsifier or surfactant include Tween 60, Tween 80, Span 80, and glyceryl monostearate.
  • Examples of the base include cetostearyl alcohol, lanolin, polyethylene glycol, rice bran oil, fish oil (DHA, EPA, etc.), olive oil and the like.
  • Examples of the solubilizer include polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate, Tween 80 and the like.
  • Examples of the suspending agent include polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate and the like in addition to the surfactant described above.
  • the metabolic syndrome improving or preventing agent of the present invention can be used as a component of medicine, food and drink (beverage, food), food and drink additive, feed, feed additive and the like.
  • examples of the beverage include water, soft drinks, fruit juice beverages, milk beverages, alcoholic beverages, sports drinks, and nutritional drinks.
  • foods include breads, noodles, rice, tofu, dairy products, soy sauce, miso, and confectionery.
  • the metabolic syndrome improving or preventing agent of the present invention can also be used as a component for food for specified health use, food for special use, dietary supplement, health food, functional food, food for sick people, and the like.
  • Beverages, foods, feeds, etc. may further contain additives usually used in the field.
  • additives include bitters, flavors, apple fiber, soybean fiber, meat extract, black vinegar extract, gelatin, corn starch, honey, animal and vegetable oils and fats; proteins such as gluten; beans such as soybeans and peas; glucose Monosaccharides such as fructose; disaccharides such as sucrose; polysaccharides such as dextrose and starch; sugar alcohols such as erythritol, xylitol, sorbitol and mannitol; vitamins such as vitamin C; minerals such as zinc, copper and magnesium Functional materials such as CoQ10, ⁇ -lipoic acid, carnitine, capsaicin; These additives can be used alone or in combination of two or more.
  • the metabolic syndrome improving or preventing agent of the present invention may be ingested by humans or non-human mammals.
  • the intake amount and the intake method can be appropriately determined according to the state, age, etc. of the individual.
  • a suitable intake method for example, oral intake can be mentioned.
  • a composition containing a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da can be used for the preparation of the metabolic syndrome improving or preventing agent of the present invention.
  • the composition may have any shape such as a solid (for example, a powder), a liquid (a water-soluble or fat-soluble solution or suspension), a paste, or the like.
  • the composition may be composed of a ⁇ -1,3-1,4-glucan degradation product having a weight average molecular weight of 1000 Da or more and less than 50000 Da.
  • composition When the composition is solid, depending on the content of the ⁇ -1,3-1,4-glucan degradation product in the composition, for example, as it is or dissolved in a solvent, It can be used as an agent for improving or preventing metabolic syndrome. In addition, when the composition is in a liquid form, it is metabolically diluted or concentrated as it is or according to the content of ⁇ -1,3-1,4-glucan degradation product in the composition. It can be used as an agent for improving or preventing syndrome.
  • the composition includes, for example, an ⁇ -amylase treatment step for decomposing a pulverized plant containing ⁇ -1,3-1,4-glucan with ⁇ -amylase, and a reaction obtained in the ⁇ -amylase treatment step. And a ⁇ -glucan degradation step of degrading ⁇ -1,3-1,4-glucan in the mixture with ⁇ -glucanase and / or cellulase.
  • the polysaccharides (such as starch) in the pulverized plant are cleaved irregularly, whereby the polysaccharides are decomposed.
  • the ⁇ -amylase treatment can be performed, for example, by adding a plant pulverized product together with ⁇ -amylase to an aqueous solvent (for example, water is preferable) and stirring it.
  • the temperature of the ⁇ -amylase treatment is preferably 70 to 100 ° C., more preferably 80 to 95 ° C., and still more preferably 85 to 95 ° C. in the case of thermostable amylase.
  • a non-thermostable amylase it is preferably 40 to 80 ° C, more preferably 50 to 70 ° C, still more preferably 55 to 65 ° C.
  • the ⁇ -amylase treatment time is, for example, preferably 15 to 90 minutes, more preferably 20 to 60 minutes, and further preferably 30 to 40 minutes.
  • the reaction mixture obtained in the ⁇ -amylase treatment step may be further decomposed with, for example, another amylolytic enzyme (for example, amyloglucosidase).
  • the above production method is obtained in the ⁇ -amylase treatment step.
  • the fraction acquisition step of obtaining a ⁇ -1,3-1,4-glucan-containing fraction from the obtained reaction mixture is preferably performed after the ⁇ -amylase treatment step.
  • the fraction is subjected to a decomposition treatment with ⁇ -glucanase and / or cellulase.
  • Solid-liquid separation can be performed by a known method (for example, centrifugation, filtration), and for example, centrifugation is suitable.
  • a precipitate by, for example, alcohol precipitation of the liquid layer.
  • alcohol used for alcohol precipitation methanol and ethanol are suitable, for example.
  • the obtained precipitate may be further subjected to a treatment such as drying (for example, freeze-drying) and pulverization.
  • the liquid layer is preferably concentrated or dried by a known method (for example, concentration under reduced pressure, freeze drying) (in this case, treatment such as pulverization may be further performed).
  • ⁇ -1,3-1,4-glucan in the reaction mixture obtained in the ⁇ -amylase treatment step is decomposed with ⁇ -glucanase and / or cellulase.
  • ⁇ -1,3-1,4-glucan for example, a ⁇ -1,3-1,4-glucan-containing fraction is combined with ⁇ -glucanase and / or cellulase and an aqueous solvent (for example, water is suitable).
  • the temperature for the decomposition treatment is, for example, preferably 40 to 70 ° C., more preferably 45 to 65 ° C., and further preferably 50 to 60 ° C.
  • the decomposition treatment time is, for example, preferably 1 to 30 minutes, more preferably 3 to 20 minutes, and further preferably 5 to 10 minutes.
  • lichenase is included in “ ⁇ -glucanase”.
  • the obtained decomposition product may be further subjected to processing such as concentration, drying, and pulverization.
  • processing such as concentration, drying, and pulverization.
  • concentration or drying a known method (for example, concentration under reduced pressure, freeze drying) can be used, and for example, freeze drying is preferable.
  • the ⁇ -amylase treatment step and the ⁇ -glucan decomposition step may be performed simultaneously. Both steps can be carried out simultaneously, for example, by adding the plant pulverized product together with ⁇ -amylase and ⁇ -glucanase to an aqueous solvent (eg water is preferred) and stirring it (with ⁇ -glucanase). Or, alternatively, cellulase may be used).
  • an aqueous solvent eg water is preferred
  • cellulase may be used.
  • the plant containing ⁇ -1,3-1,4-glucan has a high content of ⁇ -1,3-1,4-glucan.
  • Barley, oats, rye, wheat, wheat) are preferred, and barley and oats are particularly preferred.
  • a plant seed pulverized product is suitable (for example, when using a gramineous plant, any of whole grain, endosperm, silkworm, etc. may be used).
  • reaction solution was centrifuged at 8000 rpm for 20 minutes at 20 ° C., and about 14 L of the obtained translucent, high-viscosity supernatant was put into a drum can lift (250 L). Then, about 55 L of methanol was added, and after sufficient stirring, the mixture was allowed to stand for 1 hour.
  • reaction solution was poured onto a stainless steel sieve ( ⁇ 400) to separate solids.
  • a stainless steel sieve ⁇ 400
  • the solid was freeze-dried on a stainless steel pad.
  • the freeze-dried solid was intermittently pulverized with a lab miller (IFM-150, Iwatani Corporation) for 2 minutes to obtain a high molecular weight ⁇ -glucan powder.
  • the viscosity of a 0.2% aqueous solution of high molecular weight ⁇ -glucan powder was 1.97 mPa ⁇ s.
  • the weight average molecular weight of ⁇ -1,3-1,4-glucan in the high molecular weight ⁇ -glucan powder was about 500,000 Da (measurement of the weight average molecular weight was in the case of decomposed ⁇ -glucan powder (described later)). The same was done).
  • the component composition of the high molecular weight ⁇ -glucan powder was as shown in Table 1. In the table, the unit of each component amount is mass%. The amount of ⁇ -1,3-1,4-glucan was measured by fluorescence (FL) analysis using calcoflow.
  • the viscosity of a 0.2% aqueous solution of decomposed ⁇ -glucan powder was 1.02 mPa ⁇ s.
  • FIG. 1 is a molecular weight distribution curve of a ⁇ -1,3-1,4-glucan degradation product obtained by fluorescence (FL) analysis of degraded ⁇ -glucan powder.
  • FIG. 2 is a molecular weight distribution curve of a ⁇ -1,3-1,4-glucan degradation product obtained by refractive index (RI) analysis of decomposed ⁇ -glucan powder.
  • the molecular weight distribution and the weight average molecular weight were measured by gel permeation chromatography (GPC).
  • GPC conditions are as follows. Two pumps (pumps A and B) were used, and eluents A and B were allowed to flow through pumps A and B, respectively.
  • a filtrate obtained by filtering a solution of 10 mg of decomposed ⁇ -glucan powder in 10 mL of water through a 0.45 ⁇ m filter was used.
  • the molecular weight distribution and the weight average molecular weight were determined based on a calibration curve prepared using a pullulan standard (Shodex).
  • mice (Mouse grouping) 20 mice (4 weeks old, male, C57BL / 6J mice, Japanese Charles River) in good general condition, and 2 groups (control) with 10 mice in each group so that the initial body weight (average) does not vary between groups Group and decomposed ⁇ -glucan group).
  • test feed preparation of test feed
  • the test feed to be administered to each group of mice was prepared based on the powdered feed AIN93G so as to obtain the composition shown in Table 2.
  • the unit of each component amount is g / kg feed.
  • mice After one week of acclimatization, each group of mice was allowed to freely ingest a predetermined test feed and tap water for 8 weeks. Throughout the acclimatization period and subsequent test feed administration period, the mice were kept at a temperature of 22 ⁇ 3 ° C., a relative humidity of 55 ⁇ 20%, a ventilation rate of 12 times / hour, and a light / dark time of 12 hours (light period: 8 to 20 hours). Individually reared under conditions. During the acclimation breeding period, AIN93G was used as it was as feed.
  • mice of each group were subjected to cardiac blood sampling and dissection under ether anesthesia, fat weight around the epididymis, retroabdominal wall fat weight, mesenteric fat cell size, fecal total lipid. The amount, total cholesterol in feces, and bile acids in feces were measured.
  • FIG. 3 is a graph showing plasma triglyceride values of mice in each group.
  • FIG. 4 is a graph showing the plasma total cholesterol level of each group of mice.
  • FIGS. 5 and 6 are graphs showing the weight of fat around the epididymis and the weight of the abdominal wall of each group of mice, respectively. 5 and 6, the graph of (a) shows the fat weight per individual, and the graph of (b) shows the fat weight per 100 g body weight.
  • FIG. 7 is a graph showing the mesenteric adipocyte size of each group of mice.
  • FIG. 8 is a graph showing the amount of total lipid in feces of each group of mice.
  • FIG. 9 is a graph showing the total amount of cholesterol in feces of each group of mice.
  • FIG. 10 is a graph showing the amount of bile acids in the feces of each group of mice.
  • the plasma triglyceride value, the plasma total cholesterol value, the fat weight around the epididymis, the retroabdominal wall fat weight, and the mesenteric fat cell size are all in the degraded ⁇ -glucan group The value was lower than that of the control group. Further, as is clear from Tables 8 to 10 and FIGS. 8 to 10, all of the fecal total lipid amount, the fecal total cholesterol amount, and the fecal bile acid amount are all in the degraded ⁇ -glucan group as compared with the control group. Remarkably high values were shown.
  • the metabolic syndrome improving or preventing agent of the present invention suppresses visceral fat accumulation, adipocyte hypertrophy, triglyceride accumulation and cholesterol accumulation, through which visceral fat type obesity or metabolic syndrome is improved or prevented. It was confirmed that it was possible to do.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Fodder In General (AREA)

Abstract

Cette invention concerne un agent permettant d'améliorer ou de prévenir le syndrome métabolique qui comprend, à titre de principe actif, un produit de dégradation du ß-1,3-1,4-glucane ayant un poids moléculaire moyen en poids de 1000 Da ou plus et inférieur à 50000 Da. L'agent susmentionné permettant d'améliorer ou de prévenir le syndrome métabolique, qui présente une innocuité biologique élevée et peut être pris en continu tous les jours, peut être utilisé en tant que composant de médicaments, d'aliments, de boissons, et ainsi de suite. Une nouvelle composition qui peut être utilisée pour préparer l'agent susmentionné permettant d'améliorer ou de prévenir le syndrome métabolique, ainsi qu'un procédé pour la produire sont également décrits.
PCT/JP2010/054446 2009-04-09 2010-03-16 Agent permettant d'améliorer ou de prévenir le syndrome métabolique Ceased WO2010116866A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009095162A JP5506229B2 (ja) 2009-04-09 2009-04-09 メタボリックシンドローム改善又は予防剤
JP2009-095162 2009-04-09

Publications (1)

Publication Number Publication Date
WO2010116866A1 true WO2010116866A1 (fr) 2010-10-14

Family

ID=42936153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/054446 Ceased WO2010116866A1 (fr) 2009-04-09 2010-03-16 Agent permettant d'améliorer ou de prévenir le syndrome métabolique

Country Status (2)

Country Link
JP (1) JP5506229B2 (fr)
WO (1) WO2010116866A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9177804B2 (en) 2011-04-01 2015-11-03 Sumitomo Electric Industries, Ltd. Silicon carbide semiconductor device

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501799D0 (en) * 2015-02-03 2015-03-18 Tate & Lyle Sweden Ab Methods of producing liquid compositions
WO2022075222A1 (fr) * 2020-10-06 2022-04-14 株式会社Adeka Promoteur de croissance pour bactéries intestinales, agent de réduction du taux de glucose sanguin, agent hypocholestérolémiant sérique, et composition d'aliment ou de boisson le contenant

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501996A (ja) * 1996-09-25 2001-02-13 グレースリンク リミテッド β―グルカン製品および穀類からの抽出方法
WO2002098440A1 (fr) * 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Traitement antidiabetique
JP2004502794A (ja) * 2000-07-03 2004-01-29 グラナテ　シード　リミテッド 冷水可溶性β−グルカン製品およびその製造方法
JP2005307150A (ja) * 2004-03-26 2005-11-04 Asahi Denka Kogyo Kk βグルカン
JP2006028307A (ja) * 2004-07-14 2006-02-02 Asahi Denka Kogyo Kk βグルカン
JP2006521828A (ja) * 2003-04-02 2006-09-28 カーギル，インコーポレイティド 低分子量グルカンを含んでなる、改良された食物繊維含有物質
JP2007126537A (ja) * 2005-11-02 2007-05-24 Adeka Corp 高純度βグルカン組成物及びその製造方法
WO2007077929A1 (fr) * 2006-01-06 2007-07-12 Sapporo Breweries Limited Agent therapeutique pour le traitement du syndrome metabolique et aliments contenant cet agent
JP2009035732A (ja) * 2007-07-20 2009-02-19 Korea Atomic Energy Research Inst 放射線の照射による低分子量のベータグルカンの製造方法及び放射線の照射によって製造された低分子量のベータグルカン
JP2009091255A (ja) * 2007-10-03 2009-04-30 Adeka Corp 免疫調節剤
JP2009263655A (ja) * 2008-03-31 2009-11-12 Adeka Corp βグルカン組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4279984B2 (ja) * 2000-09-26 2009-06-17 パロマ工業株式会社 吸収式冷凍機
JP2007190003A (ja) * 2006-01-16 2007-08-02 Elson Kk 高血圧改善用機能性飲食品
JP2007332336A (ja) * 2006-06-13 2007-12-27 Rikomu:Kk メタボリックシンドローム治療剤

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501996A (ja) * 1996-09-25 2001-02-13 グレースリンク リミテッド β―グルカン製品および穀類からの抽出方法
JP2004502794A (ja) * 2000-07-03 2004-01-29 グラナテ　シード　リミテッド 冷水可溶性β−グルカン製品およびその製造方法
WO2002098440A1 (fr) * 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Traitement antidiabetique
JP2006521828A (ja) * 2003-04-02 2006-09-28 カーギル，インコーポレイティド 低分子量グルカンを含んでなる、改良された食物繊維含有物質
JP2005307150A (ja) * 2004-03-26 2005-11-04 Asahi Denka Kogyo Kk βグルカン
JP2006028307A (ja) * 2004-07-14 2006-02-02 Asahi Denka Kogyo Kk βグルカン
JP2007126537A (ja) * 2005-11-02 2007-05-24 Adeka Corp 高純度βグルカン組成物及びその製造方法
WO2007077929A1 (fr) * 2006-01-06 2007-07-12 Sapporo Breweries Limited Agent therapeutique pour le traitement du syndrome metabolique et aliments contenant cet agent
JP2009035732A (ja) * 2007-07-20 2009-02-19 Korea Atomic Energy Research Inst 放射線の照射による低分子量のベータグルカンの製造方法及び放射線の照射によって製造された低分子量のベータグルカン
JP2009091255A (ja) * 2007-10-03 2009-04-30 Adeka Corp 免疫調節剤
JP2009263655A (ja) * 2008-03-31 2009-11-12 Adeka Corp βグルカン組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9177804B2 (en) 2011-04-01 2015-11-03 Sumitomo Electric Industries, Ltd. Silicon carbide semiconductor device

Also Published As

Publication number Publication date
JP2010241769A (ja) 2010-10-28
JP5506229B2 (ja) 2014-05-28

Similar Documents

Publication Publication Date Title
EP2172116A1 (fr) Composition et aliment analogue au son de riz
EP2226071B1 (fr) Composition pour administration orale
JP6684966B2 (ja) 新規なラクトバチルス・サケイ及びそれを含む組成物
JP2008297209A (ja) 脂質代謝改善組成物
WO2007029631A1 (fr) Composition pour l’amélioration du métabolisme des lipides corporels
TWI380823B (zh) 脂聯素（Ａｄｉｐｏｎｅｃｔｉｎ）濃度上升劑
JP2006056836A (ja) 脂肪組織特異分泌蛋白産生増強組成物
JP6042800B2 (ja) トマトシドａの抽出方法
JP5506229B2 (ja) メタボリックシンドローム改善又は予防剤
JP5606005B2 (ja) メタボリックシンドローム改善又は予防剤
WO2009078495A1 (fr) Matière contenant des fibres alimentaires insolubles provenant de grains de céréales
WO2021173944A1 (fr) Amidon à haute résistance et son procédé de fabrication
JP2009203209A (ja) アカシア属樹皮由来物を含有する血糖降下及び／又は抗肥満組成物
JP2008063293A (ja) アディポネクチン分泌促進剤、並びに該アディポネクチン分泌促進剤を含有する中性脂肪減少剤、抗肥満剤、飲食品添加剤及び機能性食品
JP2008184459A (ja) カルシウム吸収促進組成物
JP2004161644A (ja) 膵リパーゼ阻害剤及び該阻害剤を含有する食品
JP2019052122A (ja) アディポネクチン分泌促進剤、脂肪前駆細胞分化促進剤並びにそれらを含む医薬組成物、食品及び飼料
JP2011173813A (ja) ＰＰＡＲα発現促進剤
JP4626081B2 (ja) 膵臓リパーゼ阻害剤
JP7016074B2 (ja) 中性脂肪及びコレステロール低減用組成物
JP5577019B2 (ja) 経口投与組成物
JP2010105948A (ja) 脂肪肝抑制剤
JP2010150185A (ja) メタボリックシンドローム改善又は予防剤
EP4534094A1 (fr) Composition pour prévenir, traiter ou atténuer des maladies métaboliques comprenant une souche de lactobacillus plantarum nchbl-004 ou un milieu de culture de celle-ci
KR20140115725A (ko) 울금의 커큐민을 제거한 울금 잔사를 포함하는 식욕억제 및 비만의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761567

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10761567

Country of ref document: EP

Kind code of ref document: A1